1 Min Read
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its treatment for chronic (CM) and episodic migraine (EM). AJOVY is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered as a subcutaneous injection. The PEARL study of AJOVY took place over 24 months, aiming to assess the impact of fremanezumab on […] The post Teva announces positive results from trial of AJOVY for migraine appeared first on Pharmafile.
Work & Theory on December 6, 2025
Uncategorized